Global Gastrointestinal Stromal Tumors Therapeutics Production, Demand and Key Producers, 2022-2028
This report studies the global Gastrointestinal Stromal Tumors Therapeutics demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Gastrointestinal Stromal Tumors Therapeutics, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2021 as the base year. This report explores demand trends and competition, as well as details the characteristics of Gastrointestinal Stromal Tumors Therapeutics that contribute to its increasing demand across many markets.
The global Gastrointestinal Stromal Tumors Therapeutics market size is expected to reach $ million by 2028, rising at a market growth of % CAGR during the forecast period (2022-2028).
Highlights and key features of the study
Global Gastrointestinal Stromal Tumors Therapeutics total market, 2017-2028, (USD Million)
Global Gastrointestinal Stromal Tumors Therapeutics total market by region & country, CAGR, 2017-2028, (USD Million)
U.S. VS China: Gastrointestinal Stromal Tumors Therapeutics total market, key domestic companies and share, (USD Million)
Global Gastrointestinal Stromal Tumors Therapeutics revenue by player and market share 2017-2022, (USD Million)
Global Gastrointestinal Stromal Tumors Therapeutics total market by Type, CAGR, 2017-2028, (USD Million)
Global Gastrointestinal Stromal Tumors Therapeutics total market by Application, CAGR, 2017-2028, (USD Million)
This reports profiles major players in the global Gastrointestinal Stromal Tumors Therapeutics market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Ascentage Pharma Group International, Bayer AG, Blueprint Medicines Corp, Bristol Myers Squibb Co., Deciphera Pharmaceuticals Inc, Immunicum AB, Novartis AG, Pfizer Inc. and Sun Pharmaceutical Industries Ltd, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Gastrointestinal Stromal Tumors Therapeutics market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2017-2028 by year with 2021 as the base year, 2022 as the estimate year, and 2028 as the forecast year.
Global Gastrointestinal Stromal Tumors Therapeutics Market, By Region:
1. How big is the global Gastrointestinal Stromal Tumors Therapeutics market?
2. What is the demand of the global Gastrointestinal Stromal Tumors Therapeutics market?
3. What is the year over year growth of the global Gastrointestinal Stromal Tumors Therapeutics market?
4. What is the total value of the global Gastrointestinal Stromal Tumors Therapeutics market?
5. Who are the major players in the global Gastrointestinal Stromal Tumors Therapeutics market?
6. What are the growth factors driving the market demand?
This report is a detailed and comprehensive analysis of the world market for Gastrointestinal Stromal Tumors Therapeutics, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2021 as the base year. This report explores demand trends and competition, as well as details the characteristics of Gastrointestinal Stromal Tumors Therapeutics that contribute to its increasing demand across many markets.
The global Gastrointestinal Stromal Tumors Therapeutics market size is expected to reach $ million by 2028, rising at a market growth of % CAGR during the forecast period (2022-2028).
Highlights and key features of the study
Global Gastrointestinal Stromal Tumors Therapeutics total market, 2017-2028, (USD Million)
Global Gastrointestinal Stromal Tumors Therapeutics total market by region & country, CAGR, 2017-2028, (USD Million)
U.S. VS China: Gastrointestinal Stromal Tumors Therapeutics total market, key domestic companies and share, (USD Million)
Global Gastrointestinal Stromal Tumors Therapeutics revenue by player and market share 2017-2022, (USD Million)
Global Gastrointestinal Stromal Tumors Therapeutics total market by Type, CAGR, 2017-2028, (USD Million)
Global Gastrointestinal Stromal Tumors Therapeutics total market by Application, CAGR, 2017-2028, (USD Million)
This reports profiles major players in the global Gastrointestinal Stromal Tumors Therapeutics market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Ascentage Pharma Group International, Bayer AG, Blueprint Medicines Corp, Bristol Myers Squibb Co., Deciphera Pharmaceuticals Inc, Immunicum AB, Novartis AG, Pfizer Inc. and Sun Pharmaceutical Industries Ltd, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Gastrointestinal Stromal Tumors Therapeutics market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2017-2028 by year with 2021 as the base year, 2022 as the estimate year, and 2028 as the forecast year.
Global Gastrointestinal Stromal Tumors Therapeutics Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Oral
- Non-oral
- Hospital
- Clinic
- Others
- Ascentage Pharma Group International
- Bayer AG
- Blueprint Medicines Corp
- Bristol Myers Squibb Co.
- Deciphera Pharmaceuticals Inc
- Immunicum AB
- Novartis AG
- Pfizer Inc.
- Sun Pharmaceutical Industries Ltd
- Xencor Inc.
1. How big is the global Gastrointestinal Stromal Tumors Therapeutics market?
2. What is the demand of the global Gastrointestinal Stromal Tumors Therapeutics market?
3. What is the year over year growth of the global Gastrointestinal Stromal Tumors Therapeutics market?
4. What is the total value of the global Gastrointestinal Stromal Tumors Therapeutics market?
5. Who are the major players in the global Gastrointestinal Stromal Tumors Therapeutics market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Gastrointestinal Stromal Tumors Therapeutics Introduction
1.2 World Gastrointestinal Stromal Tumors Therapeutics Market Size & Forecast (2017 & 2021 & 2028)
1.3 World Gastrointestinal Stromal Tumors Therapeutics Total Market by Region
1.3.1 World Gastrointestinal Stromal Tumors Therapeutics Market Size by Region (2017-2028)
1.3.2 United States Gastrointestinal Stromal Tumors Therapeutics Market Size (2017-2028)
1.3.3 China Gastrointestinal Stromal Tumors Therapeutics Market Size (2017-2028)
1.3.4 Europe Gastrointestinal Stromal Tumors Therapeutics Market Size (2017-2028)
1.3.5 Japan Gastrointestinal Stromal Tumors Therapeutics Market Size (2017-2028)
1.3.6 South Korea Gastrointestinal Stromal Tumors Therapeutics Market Size (2017-2028)
1.3.7 ASEAN Gastrointestinal Stromal Tumors Therapeutics Market Size (2017-2028)
1.3.8 India Gastrointestinal Stromal Tumors Therapeutics Market Size (2017-2028)
1.4 Market Drivers, Restraints and Trends
1.4.1 Gastrointestinal Stromal Tumors Therapeutics Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Gastrointestinal Stromal Tumors Therapeutics Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
1.5.1 Influence of COVID-19
1.5.2 Influence of Russia-Ukraine War
2 WORLD GASTROINTESTINAL STROMAL TUMORS THERAPEUTICS COMPANIES COMPETITIVE ANALYSIS
2.1 World Gastrointestinal Stromal Tumors Therapeutics Revenue by Player (2017-2022)
2.2 Industry Rank and Concentration Rate (CR)
2.2.1 Global Gastrointestinal Stromal Tumors Therapeutics Industry Rank of Major Players
2.2.2 Global Concentration Ratios (CR4) for Gastrointestinal Stromal Tumors Therapeutics in 2021
2.2.3 Global Concentration Ratios (CR8) for Gastrointestinal Stromal Tumors Therapeutics in 2021
2.3 Gastrointestinal Stromal Tumors Therapeutics Company Evaluation Quadrant
2.4 Gastrointestinal Stromal Tumors Therapeutics Market: Overall Company Footprint Analysis
2.4.1 Gastrointestinal Stromal Tumors Therapeutics Market: Region Footprint
2.4.2 Gastrointestinal Stromal Tumors Therapeutics Market: Company Product Type Footprint
2.4.3 Gastrointestinal Stromal Tumors Therapeutics Market: Company Product Application Footprint
2.5 Competitive Environment
2.5.1 Historical Structure of the Industry
2.5.2 Barriers of Market Entry
2.5.3 Factors of Competition
2.6 Mergers, Acquisitions Activity
3 UNITED STATES VS CHINA VS REST OF THE WORLD
3.1 United States VS China: Gastrointestinal Stromal Tumors Therapeutics Market Comparison
3.1.1 United States VS China: Gastrointestinal Stromal Tumors Therapeutics Market Size Comparison (2017 & 2021 & 2028)
3.1.2 United States VS China: Gastrointestinal Stromal Tumors Therapeutics Market Size Market Share Comparison (2017 & 2021 & 2028)
3.2 United States Gastrointestinal Stromal Tumors Therapeutics Major Players and Market Share, 2017-2022
3.2.1 Major Players of Gastrointestinal Stromal Tumors Therapeutics in United States, Headquarters (States, Country)
3.2.2 United States Gastrointestinal Stromal Tumors Therapeutics Revenue by Domestic Player, (2017-2022)
3.3 China Gastrointestinal Stromal Tumors Therapeutics Major Players and Market Share, 2017-2022
3.3.1 Major Players of Gastrointestinal Stromal Tumors Therapeutics in China, Headquarters (Province, Country)
3.3.2 China Gastrointestinal Stromal Tumors Therapeutics Revenue by Domestic Player, (2017-2022)
3.4 Rest of World Gastrointestinal Stromal Tumors Therapeutics Major Players and Market Share, 2017-2022
3.4.1 Major Players of Gastrointestinal Stromal Tumors Therapeutics in Rest of World, Headquarters (State, Country)
3.4.2 Rest of World Gastrointestinal Stromal Tumors Therapeutics Revenue by Domestic Player, (2017-2022)
4 MARKET ANALYSIS BY TYPE
4.1 World Gastrointestinal Stromal Tumors Therapeutics Market Size Overview by Type: 2017 VS 2021 VS 2028
4.2 Segment Introduction by Type
4.2.1 Oral
4.2.2 Non-oral
4.3 Market Segment by Type
4.3.1 World Gastrointestinal Stromal Tumors Therapeutics Market Size by Type (2017-2022)
4.3.2 World Gastrointestinal Stromal Tumors Therapeutics Market Size by Type (2023-2028)
4.3.3 World Gastrointestinal Stromal Tumors Therapeutics Market Size Market Share by Type (2017-2028)
5 MARKET ANALYSIS BY APPLICATION
5.1 World Gastrointestinal Stromal Tumors Therapeutics Market Size Overview by Application: 2017 VS 2021 VS 2028
5.2 Segment Introduction by Application
5.2.1 Hospital
5.2.2 Clinic
5.2.3 Others
5.3 Market Segment by Application
5.3.1 World Gastrointestinal Stromal Tumors Therapeutics Market Size by Application (2017-2022)
5.3.2 World Gastrointestinal Stromal Tumors Therapeutics Market Size by Application (2023-2028)
5.3.3 World Gastrointestinal Stromal Tumors Therapeutics Market Size by Application (2017-2028)
6 COMPANY PROFILES
6.1 Ascentage Pharma Group International
6.1.1 Ascentage Pharma Group International Details
6.1.2 Ascentage Pharma Group International Major Business
6.1.3 Ascentage Pharma Group International Gastrointestinal Stromal Tumors Therapeutics Product and Services
6.1.4 Ascentage Pharma Group International Gastrointestinal Stromal Tumors Therapeutics Revenue, Gross Margin and Market Share (2017-2022)
6.1.5 Ascentage Pharma Group International Recent Developments/Updates
6.1.6 Ascentage Pharma Group International Competitive Strengths & Weaknesses
6.2 Bayer AG
6.2.1 Bayer AG Details
6.2.2 Bayer AG Major Business
6.2.3 Bayer AG Gastrointestinal Stromal Tumors Therapeutics Product and Services
6.2.4 Bayer AG Gastrointestinal Stromal Tumors Therapeutics Revenue, Gross Margin and Market Share (2017-2022)
6.2.5 Bayer AG Recent Developments/Updates
6.2.6 Bayer AG Competitive Strengths & Weaknesses
6.3 Blueprint Medicines Corp
6.3.1 Blueprint Medicines Corp Details
6.3.2 Blueprint Medicines Corp Major Business
6.3.3 Blueprint Medicines Corp Gastrointestinal Stromal Tumors Therapeutics Product and Services
6.3.4 Blueprint Medicines Corp Gastrointestinal Stromal Tumors Therapeutics Revenue, Gross Margin and Market Share (2017-2022)
6.3.5 Blueprint Medicines Corp Recent Developments/Updates
6.3.6 Blueprint Medicines Corp Competitive Strengths & Weaknesses
6.4 Bristol Myers Squibb Co.
6.4.1 Bristol Myers Squibb Co. Details
6.4.2 Bristol Myers Squibb Co. Major Business
6.4.3 Bristol Myers Squibb Co. Gastrointestinal Stromal Tumors Therapeutics Product and Services
6.4.4 Bristol Myers Squibb Co. Gastrointestinal Stromal Tumors Therapeutics Revenue, Gross Margin and Market Share (2017-2022)
6.4.5 Bristol Myers Squibb Co. Recent Developments/Updates
6.4.6 Bristol Myers Squibb Co. Competitive Strengths & Weaknesses
6.5 Deciphera Pharmaceuticals Inc
6.5.1 Deciphera Pharmaceuticals Inc Details
6.5.2 Deciphera Pharmaceuticals Inc Major Business
6.5.3 Deciphera Pharmaceuticals Inc Gastrointestinal Stromal Tumors Therapeutics Product and Services
6.5.4 Deciphera Pharmaceuticals Inc Gastrointestinal Stromal Tumors Therapeutics Revenue, Gross Margin and Market Share (2017-2022)
6.5.5 Deciphera Pharmaceuticals Inc Recent Developments/Updates
6.5.6 Deciphera Pharmaceuticals Inc Competitive Strengths & Weaknesses
6.6 Immunicum AB
6.6.1 Immunicum AB Details
6.6.2 Immunicum AB Major Business
6.6.3 Immunicum AB Gastrointestinal Stromal Tumors Therapeutics Product and Services
6.6.4 Immunicum AB Gastrointestinal Stromal Tumors Therapeutics Revenue, Gross Margin and Market Share (2017-2022)
6.6.5 Immunicum AB Recent Developments/Updates
6.6.6 Immunicum AB Competitive Strengths & Weaknesses
6.7 Novartis AG
6.7.1 Novartis AG Details
6.7.2 Novartis AG Major Business
6.7.3 Novartis AG Gastrointestinal Stromal Tumors Therapeutics Product and Services
6.7.4 Novartis AG Gastrointestinal Stromal Tumors Therapeutics Revenue, Gross Margin and Market Share (2017-2022)
6.7.5 Novartis AG Recent Developments/Updates
6.7.6 Novartis AG Competitive Strengths & Weaknesses
6.8 Pfizer Inc.
6.8.1 Pfizer Inc. Details
6.8.2 Pfizer Inc. Major Business
6.8.3 Pfizer Inc. Gastrointestinal Stromal Tumors Therapeutics Product and Services
6.8.4 Pfizer Inc. Gastrointestinal Stromal Tumors Therapeutics Revenue, Gross Margin and Market Share (2017-2022)
6.8.5 Pfizer Inc. Recent Developments/Updates
6.8.6 Pfizer Inc. Competitive Strengths & Weaknesses
6.9 Sun Pharmaceutical Industries Ltd
6.9.1 Sun Pharmaceutical Industries Ltd Details
6.9.2 Sun Pharmaceutical Industries Ltd Major Business
6.9.3 Sun Pharmaceutical Industries Ltd Gastrointestinal Stromal Tumors Therapeutics Product and Services
6.9.4 Sun Pharmaceutical Industries Ltd Gastrointestinal Stromal Tumors Therapeutics Revenue, Gross Margin and Market Share (2017-2022)
6.9.5 Sun Pharmaceutical Industries Ltd Recent Developments/Updates
6.9.6 Sun Pharmaceutical Industries Ltd Competitive Strengths & Weaknesses
6.10 Xencor Inc.
6.10.1 Xencor Inc. Details
6.10.2 Xencor Inc. Major Business
6.10.3 Xencor Inc. Gastrointestinal Stromal Tumors Therapeutics Product and Services
6.10.4 Xencor Inc. Gastrointestinal Stromal Tumors Therapeutics Revenue, Gross Margin and Market Share (2017-2022)
6.10.5 Xencor Inc. Recent Developments/Updates
6.10.6 Xencor Inc. Competitive Strengths & Weaknesses
7 RAW MATERIAL AND INDUSTRY CHAIN
7.1 Raw Material of Gastrointestinal Stromal Tumors Therapeutics and Key Manufacturers
7.2 Gastrointestinal Stromal Tumors Therapeutics Manufacturing Costs
7.3 Gastrointestinal Stromal Tumors Therapeutics Production Process
7.4 Gastrointestinal Stromal Tumors Therapeutics Industrial Chain
8 DISTRIBUTION CHANNEL ANALYSIS
8.1 Distribution Channel Breakdown for Gastrointestinal Stromal Tumors Therapeutics Shipments (%): 2017-2028
8.1.1 Direct Channel
8.1.2 Indirect Channel
8.2 Gastrointestinal Stromal Tumors Therapeutics Typical Distributors
8.3 Gastrointestinal Stromal Tumors Therapeutics Typical Customers
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
1.1 Gastrointestinal Stromal Tumors Therapeutics Introduction
1.2 World Gastrointestinal Stromal Tumors Therapeutics Market Size & Forecast (2017 & 2021 & 2028)
1.3 World Gastrointestinal Stromal Tumors Therapeutics Total Market by Region
1.3.1 World Gastrointestinal Stromal Tumors Therapeutics Market Size by Region (2017-2028)
1.3.2 United States Gastrointestinal Stromal Tumors Therapeutics Market Size (2017-2028)
1.3.3 China Gastrointestinal Stromal Tumors Therapeutics Market Size (2017-2028)
1.3.4 Europe Gastrointestinal Stromal Tumors Therapeutics Market Size (2017-2028)
1.3.5 Japan Gastrointestinal Stromal Tumors Therapeutics Market Size (2017-2028)
1.3.6 South Korea Gastrointestinal Stromal Tumors Therapeutics Market Size (2017-2028)
1.3.7 ASEAN Gastrointestinal Stromal Tumors Therapeutics Market Size (2017-2028)
1.3.8 India Gastrointestinal Stromal Tumors Therapeutics Market Size (2017-2028)
1.4 Market Drivers, Restraints and Trends
1.4.1 Gastrointestinal Stromal Tumors Therapeutics Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Gastrointestinal Stromal Tumors Therapeutics Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
1.5.1 Influence of COVID-19
1.5.2 Influence of Russia-Ukraine War
2 WORLD GASTROINTESTINAL STROMAL TUMORS THERAPEUTICS COMPANIES COMPETITIVE ANALYSIS
2.1 World Gastrointestinal Stromal Tumors Therapeutics Revenue by Player (2017-2022)
2.2 Industry Rank and Concentration Rate (CR)
2.2.1 Global Gastrointestinal Stromal Tumors Therapeutics Industry Rank of Major Players
2.2.2 Global Concentration Ratios (CR4) for Gastrointestinal Stromal Tumors Therapeutics in 2021
2.2.3 Global Concentration Ratios (CR8) for Gastrointestinal Stromal Tumors Therapeutics in 2021
2.3 Gastrointestinal Stromal Tumors Therapeutics Company Evaluation Quadrant
2.4 Gastrointestinal Stromal Tumors Therapeutics Market: Overall Company Footprint Analysis
2.4.1 Gastrointestinal Stromal Tumors Therapeutics Market: Region Footprint
2.4.2 Gastrointestinal Stromal Tumors Therapeutics Market: Company Product Type Footprint
2.4.3 Gastrointestinal Stromal Tumors Therapeutics Market: Company Product Application Footprint
2.5 Competitive Environment
2.5.1 Historical Structure of the Industry
2.5.2 Barriers of Market Entry
2.5.3 Factors of Competition
2.6 Mergers, Acquisitions Activity
3 UNITED STATES VS CHINA VS REST OF THE WORLD
3.1 United States VS China: Gastrointestinal Stromal Tumors Therapeutics Market Comparison
3.1.1 United States VS China: Gastrointestinal Stromal Tumors Therapeutics Market Size Comparison (2017 & 2021 & 2028)
3.1.2 United States VS China: Gastrointestinal Stromal Tumors Therapeutics Market Size Market Share Comparison (2017 & 2021 & 2028)
3.2 United States Gastrointestinal Stromal Tumors Therapeutics Major Players and Market Share, 2017-2022
3.2.1 Major Players of Gastrointestinal Stromal Tumors Therapeutics in United States, Headquarters (States, Country)
3.2.2 United States Gastrointestinal Stromal Tumors Therapeutics Revenue by Domestic Player, (2017-2022)
3.3 China Gastrointestinal Stromal Tumors Therapeutics Major Players and Market Share, 2017-2022
3.3.1 Major Players of Gastrointestinal Stromal Tumors Therapeutics in China, Headquarters (Province, Country)
3.3.2 China Gastrointestinal Stromal Tumors Therapeutics Revenue by Domestic Player, (2017-2022)
3.4 Rest of World Gastrointestinal Stromal Tumors Therapeutics Major Players and Market Share, 2017-2022
3.4.1 Major Players of Gastrointestinal Stromal Tumors Therapeutics in Rest of World, Headquarters (State, Country)
3.4.2 Rest of World Gastrointestinal Stromal Tumors Therapeutics Revenue by Domestic Player, (2017-2022)
4 MARKET ANALYSIS BY TYPE
4.1 World Gastrointestinal Stromal Tumors Therapeutics Market Size Overview by Type: 2017 VS 2021 VS 2028
4.2 Segment Introduction by Type
4.2.1 Oral
4.2.2 Non-oral
4.3 Market Segment by Type
4.3.1 World Gastrointestinal Stromal Tumors Therapeutics Market Size by Type (2017-2022)
4.3.2 World Gastrointestinal Stromal Tumors Therapeutics Market Size by Type (2023-2028)
4.3.3 World Gastrointestinal Stromal Tumors Therapeutics Market Size Market Share by Type (2017-2028)
5 MARKET ANALYSIS BY APPLICATION
5.1 World Gastrointestinal Stromal Tumors Therapeutics Market Size Overview by Application: 2017 VS 2021 VS 2028
5.2 Segment Introduction by Application
5.2.1 Hospital
5.2.2 Clinic
5.2.3 Others
5.3 Market Segment by Application
5.3.1 World Gastrointestinal Stromal Tumors Therapeutics Market Size by Application (2017-2022)
5.3.2 World Gastrointestinal Stromal Tumors Therapeutics Market Size by Application (2023-2028)
5.3.3 World Gastrointestinal Stromal Tumors Therapeutics Market Size by Application (2017-2028)
6 COMPANY PROFILES
6.1 Ascentage Pharma Group International
6.1.1 Ascentage Pharma Group International Details
6.1.2 Ascentage Pharma Group International Major Business
6.1.3 Ascentage Pharma Group International Gastrointestinal Stromal Tumors Therapeutics Product and Services
6.1.4 Ascentage Pharma Group International Gastrointestinal Stromal Tumors Therapeutics Revenue, Gross Margin and Market Share (2017-2022)
6.1.5 Ascentage Pharma Group International Recent Developments/Updates
6.1.6 Ascentage Pharma Group International Competitive Strengths & Weaknesses
6.2 Bayer AG
6.2.1 Bayer AG Details
6.2.2 Bayer AG Major Business
6.2.3 Bayer AG Gastrointestinal Stromal Tumors Therapeutics Product and Services
6.2.4 Bayer AG Gastrointestinal Stromal Tumors Therapeutics Revenue, Gross Margin and Market Share (2017-2022)
6.2.5 Bayer AG Recent Developments/Updates
6.2.6 Bayer AG Competitive Strengths & Weaknesses
6.3 Blueprint Medicines Corp
6.3.1 Blueprint Medicines Corp Details
6.3.2 Blueprint Medicines Corp Major Business
6.3.3 Blueprint Medicines Corp Gastrointestinal Stromal Tumors Therapeutics Product and Services
6.3.4 Blueprint Medicines Corp Gastrointestinal Stromal Tumors Therapeutics Revenue, Gross Margin and Market Share (2017-2022)
6.3.5 Blueprint Medicines Corp Recent Developments/Updates
6.3.6 Blueprint Medicines Corp Competitive Strengths & Weaknesses
6.4 Bristol Myers Squibb Co.
6.4.1 Bristol Myers Squibb Co. Details
6.4.2 Bristol Myers Squibb Co. Major Business
6.4.3 Bristol Myers Squibb Co. Gastrointestinal Stromal Tumors Therapeutics Product and Services
6.4.4 Bristol Myers Squibb Co. Gastrointestinal Stromal Tumors Therapeutics Revenue, Gross Margin and Market Share (2017-2022)
6.4.5 Bristol Myers Squibb Co. Recent Developments/Updates
6.4.6 Bristol Myers Squibb Co. Competitive Strengths & Weaknesses
6.5 Deciphera Pharmaceuticals Inc
6.5.1 Deciphera Pharmaceuticals Inc Details
6.5.2 Deciphera Pharmaceuticals Inc Major Business
6.5.3 Deciphera Pharmaceuticals Inc Gastrointestinal Stromal Tumors Therapeutics Product and Services
6.5.4 Deciphera Pharmaceuticals Inc Gastrointestinal Stromal Tumors Therapeutics Revenue, Gross Margin and Market Share (2017-2022)
6.5.5 Deciphera Pharmaceuticals Inc Recent Developments/Updates
6.5.6 Deciphera Pharmaceuticals Inc Competitive Strengths & Weaknesses
6.6 Immunicum AB
6.6.1 Immunicum AB Details
6.6.2 Immunicum AB Major Business
6.6.3 Immunicum AB Gastrointestinal Stromal Tumors Therapeutics Product and Services
6.6.4 Immunicum AB Gastrointestinal Stromal Tumors Therapeutics Revenue, Gross Margin and Market Share (2017-2022)
6.6.5 Immunicum AB Recent Developments/Updates
6.6.6 Immunicum AB Competitive Strengths & Weaknesses
6.7 Novartis AG
6.7.1 Novartis AG Details
6.7.2 Novartis AG Major Business
6.7.3 Novartis AG Gastrointestinal Stromal Tumors Therapeutics Product and Services
6.7.4 Novartis AG Gastrointestinal Stromal Tumors Therapeutics Revenue, Gross Margin and Market Share (2017-2022)
6.7.5 Novartis AG Recent Developments/Updates
6.7.6 Novartis AG Competitive Strengths & Weaknesses
6.8 Pfizer Inc.
6.8.1 Pfizer Inc. Details
6.8.2 Pfizer Inc. Major Business
6.8.3 Pfizer Inc. Gastrointestinal Stromal Tumors Therapeutics Product and Services
6.8.4 Pfizer Inc. Gastrointestinal Stromal Tumors Therapeutics Revenue, Gross Margin and Market Share (2017-2022)
6.8.5 Pfizer Inc. Recent Developments/Updates
6.8.6 Pfizer Inc. Competitive Strengths & Weaknesses
6.9 Sun Pharmaceutical Industries Ltd
6.9.1 Sun Pharmaceutical Industries Ltd Details
6.9.2 Sun Pharmaceutical Industries Ltd Major Business
6.9.3 Sun Pharmaceutical Industries Ltd Gastrointestinal Stromal Tumors Therapeutics Product and Services
6.9.4 Sun Pharmaceutical Industries Ltd Gastrointestinal Stromal Tumors Therapeutics Revenue, Gross Margin and Market Share (2017-2022)
6.9.5 Sun Pharmaceutical Industries Ltd Recent Developments/Updates
6.9.6 Sun Pharmaceutical Industries Ltd Competitive Strengths & Weaknesses
6.10 Xencor Inc.
6.10.1 Xencor Inc. Details
6.10.2 Xencor Inc. Major Business
6.10.3 Xencor Inc. Gastrointestinal Stromal Tumors Therapeutics Product and Services
6.10.4 Xencor Inc. Gastrointestinal Stromal Tumors Therapeutics Revenue, Gross Margin and Market Share (2017-2022)
6.10.5 Xencor Inc. Recent Developments/Updates
6.10.6 Xencor Inc. Competitive Strengths & Weaknesses
7 RAW MATERIAL AND INDUSTRY CHAIN
7.1 Raw Material of Gastrointestinal Stromal Tumors Therapeutics and Key Manufacturers
7.2 Gastrointestinal Stromal Tumors Therapeutics Manufacturing Costs
7.3 Gastrointestinal Stromal Tumors Therapeutics Production Process
7.4 Gastrointestinal Stromal Tumors Therapeutics Industrial Chain
8 DISTRIBUTION CHANNEL ANALYSIS
8.1 Distribution Channel Breakdown for Gastrointestinal Stromal Tumors Therapeutics Shipments (%): 2017-2028
8.1.1 Direct Channel
8.1.2 Indirect Channel
8.2 Gastrointestinal Stromal Tumors Therapeutics Typical Distributors
8.3 Gastrointestinal Stromal Tumors Therapeutics Typical Customers
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
LIST OF TABLES
Table 1. World Gastrointestinal Stromal Tumors Therapeutics Market Size by Region (2017, 2022 and 2028) & (USD Million)
Table 2. World Gastrointestinal Stromal Tumors Therapeutics Market Size by Region (2017-2022) & (USD Million)
Table 3. World Gastrointestinal Stromal Tumors Therapeutics Market Size by Region (2023-2028) & (USD Million)
Table 4. World Gastrointestinal Stromal Tumors Therapeutics Market Size Market Share by Region (2017-2022)
Table 5. World Gastrointestinal Stromal Tumors Therapeutics Market Size Market Share by Region (2023-2028)
Table 6. Major Market Trends
Table 7. World Gastrointestinal Stromal Tumors Therapeutics Revenue by Player (2017-2022) & (USD Million)
Table 8. Revenue Market Share of Key Gastrointestinal Stromal Tumors Therapeutics Players in 2021
Table 9. World Gastrointestinal Stromal Tumors Therapeutics Industry Rank of Major Player, Based on Revenue in 2021
Table 10. Global Gastrointestinal Stromal Tumors Therapeutics Company Evaluation Quadrant
Table 11. Head Office of Key Gastrointestinal Stromal Tumors Therapeutics Player
Table 12. Gastrointestinal Stromal Tumors Therapeutics Market: Company Product Type Footprint
Table 13. Gastrointestinal Stromal Tumors Therapeutics Market: Company Product Application Footprint
Table 14. Gastrointestinal Stromal Tumors Therapeutics Mergers & Acquisitions Activity
Table 15. United States VS China Gastrointestinal Stromal Tumors Therapeutics Market Size Comparison, (2017 & 2021 & 2028) & (USD Million)
Table 16. Major Player of Gastrointestinal Stromal Tumors Therapeutics in United States, Headquarters (States, Country)
Table 17. United States Gastrointestinal Stromal Tumors Therapeutics Revenue by Domestic Player, (2017-2022) & (USD Million)
Table 18. United States Gastrointestinal Stromal Tumors Therapeutics Revenue Market Share by Domestic Player, (2017-2022)
Table 19. Major Player of Gastrointestinal Stromal Tumors Therapeutics in China, Company Headquarters (Province, Country)
Table 20. China Gastrointestinal Stromal Tumors Therapeutics Revenue by Domestic Player, (2017-2022) & (USD Million)
Table 21. China Gastrointestinal Stromal Tumors Therapeutics Revenue Market Share by Domestic Player, (2017-2022)
Table 22. Major Player of Gastrointestinal Stromal Tumors Therapeutics in Rest of World, Company Headquarters (State, Country)
Table 23. Rest of World Gastrointestinal Stromal Tumors Therapeutics Revenue by Domestic Player, (2017-2022) & (USD Million)
Table 24. Rest of World Gastrointestinal Stromal Tumors Therapeutics Revenue Market Share by Domestic Player, (2017-2022)
Table 25. World Gastrointestinal Stromal Tumors Therapeutics Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 26. World Gastrointestinal Stromal Tumors Therapeutics Revenue by Type (2017-2022) & (USD Million)
Table 27. World Gastrointestinal Stromal Tumors Therapeutics Revenue by Type (2023-2028) & (USD Million)
Table 28. World Gastrointestinal Stromal Tumors Therapeutics Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 29. World Gastrointestinal Stromal Tumors Therapeutics Revenue by Application (2017-2022) & (USD Million)
Table 30. World Gastrointestinal Stromal Tumors Therapeutics Revenue by Application (2023-2028) & (USD Million)
Table 31. Ascentage Pharma Group International Basic Information, Area Served and Competitors
Table 32. Ascentage Pharma Group International Major Business
Table 33. Ascentage Pharma Group International Gastrointestinal Stromal Tumors Therapeutics Product and Services
Table 34. Ascentage Pharma Group International Gastrointestinal Stromal Tumors Therapeutics Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 35. Ascentage Pharma Group International Recent Developments/Updates
Table 36. Ascentage Pharma Group International Competitive Strengths & Weaknesses
Table 37. Bayer AG Basic Information, Area Served and Competitors
Table 38. Bayer AG Major Business
Table 39. Bayer AG Gastrointestinal Stromal Tumors Therapeutics Product and Services
Table 40. Bayer AG Gastrointestinal Stromal Tumors Therapeutics Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 41. Bayer AG Recent Developments/Updates
Table 42. Bayer AG Competitive Strengths & Weaknesses
Table 43. Blueprint Medicines Corp Basic Information, Area Served and Competitors
Table 44. Blueprint Medicines Corp Major Business
Table 45. Blueprint Medicines Corp Gastrointestinal Stromal Tumors Therapeutics Product and Services
Table 46. Blueprint Medicines Corp Gastrointestinal Stromal Tumors Therapeutics Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 47. Blueprint Medicines Corp Recent Developments/Updates
Table 48. Blueprint Medicines Corp Competitive Strengths & Weaknesses
Table 49. Bristol Myers Squibb Co. Basic Information, Area Served and Competitors
Table 50. Bristol Myers Squibb Co. Major Business
Table 51. Bristol Myers Squibb Co. Gastrointestinal Stromal Tumors Therapeutics Product and Services
Table 52. Bristol Myers Squibb Co. Gastrointestinal Stromal Tumors Therapeutics Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 53. Bristol Myers Squibb Co. Recent Developments/Updates
Table 54. Bristol Myers Squibb Co. Competitive Strengths & Weaknesses
Table 55. Deciphera Pharmaceuticals Inc Basic Information, Area Served and Competitors
Table 56. Deciphera Pharmaceuticals Inc Major Business
Table 57. Deciphera Pharmaceuticals Inc Gastrointestinal Stromal Tumors Therapeutics Product and Services
Table 58. Deciphera Pharmaceuticals Inc Gastrointestinal Stromal Tumors Therapeutics Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 59. Deciphera Pharmaceuticals Inc Recent Developments/Updates
Table 60. Deciphera Pharmaceuticals Inc Competitive Strengths & Weaknesses
Table 61. Immunicum AB Basic Information, Area Served and Competitors
Table 62. Immunicum AB Major Business
Table 63. Immunicum AB Gastrointestinal Stromal Tumors Therapeutics Product and Services
Table 64. Immunicum AB Gastrointestinal Stromal Tumors Therapeutics Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 65. Immunicum AB Recent Developments/Updates
Table 66. Immunicum AB Competitive Strengths & Weaknesses
Table 67. Novartis AG Basic Information, Area Served and Competitors
Table 68. Novartis AG Major Business
Table 69. Novartis AG Gastrointestinal Stromal Tumors Therapeutics Product and Services
Table 70. Novartis AG Gastrointestinal Stromal Tumors Therapeutics Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 71. Novartis AG Recent Developments/Updates
Table 72. Novartis AG Competitive Strengths & Weaknesses
Table 73. Pfizer Inc. Basic Information, Area Served and Competitors
Table 74. Pfizer Inc. Major Business
Table 75. Pfizer Inc. Gastrointestinal Stromal Tumors Therapeutics Product and Services
Table 76. Pfizer Inc. Gastrointestinal Stromal Tumors Therapeutics Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 77. Pfizer Inc. Recent Developments/Updates
Table 78. Pfizer Inc. Competitive Strengths & Weaknesses
Table 79. Sun Pharmaceutical Industries Ltd Basic Information, Area Served and Competitors
Table 80. Sun Pharmaceutical Industries Ltd Major Business
Table 81. Sun Pharmaceutical Industries Ltd Gastrointestinal Stromal Tumors Therapeutics Product and Services
Table 82. Sun Pharmaceutical Industries Ltd Gastrointestinal Stromal Tumors Therapeutics Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 83. Sun Pharmaceutical Industries Ltd Recent Developments/Updates
Table 84. Xencor Inc. Basic Information, Area Served and Competitors
Table 85. Xencor Inc. Major Business
Table 86. Xencor Inc. Gastrointestinal Stromal Tumors Therapeutics Product and Services
Table 87. Xencor Inc. Gastrointestinal Stromal Tumors Therapeutics Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 88. Gastrointestinal Stromal Tumors Therapeutics Raw Material
Table 89. Key Manufacturers of Gastrointestinal Stromal Tumors Therapeutics Raw Materials
Table 90. Gastrointestinal Stromal Tumors Therapeutics Typical Distributors
Table 91. Gastrointestinal Stromal Tumors Therapeutics Typical Customers
Table 1. World Gastrointestinal Stromal Tumors Therapeutics Market Size by Region (2017, 2022 and 2028) & (USD Million)
Table 2. World Gastrointestinal Stromal Tumors Therapeutics Market Size by Region (2017-2022) & (USD Million)
Table 3. World Gastrointestinal Stromal Tumors Therapeutics Market Size by Region (2023-2028) & (USD Million)
Table 4. World Gastrointestinal Stromal Tumors Therapeutics Market Size Market Share by Region (2017-2022)
Table 5. World Gastrointestinal Stromal Tumors Therapeutics Market Size Market Share by Region (2023-2028)
Table 6. Major Market Trends
Table 7. World Gastrointestinal Stromal Tumors Therapeutics Revenue by Player (2017-2022) & (USD Million)
Table 8. Revenue Market Share of Key Gastrointestinal Stromal Tumors Therapeutics Players in 2021
Table 9. World Gastrointestinal Stromal Tumors Therapeutics Industry Rank of Major Player, Based on Revenue in 2021
Table 10. Global Gastrointestinal Stromal Tumors Therapeutics Company Evaluation Quadrant
Table 11. Head Office of Key Gastrointestinal Stromal Tumors Therapeutics Player
Table 12. Gastrointestinal Stromal Tumors Therapeutics Market: Company Product Type Footprint
Table 13. Gastrointestinal Stromal Tumors Therapeutics Market: Company Product Application Footprint
Table 14. Gastrointestinal Stromal Tumors Therapeutics Mergers & Acquisitions Activity
Table 15. United States VS China Gastrointestinal Stromal Tumors Therapeutics Market Size Comparison, (2017 & 2021 & 2028) & (USD Million)
Table 16. Major Player of Gastrointestinal Stromal Tumors Therapeutics in United States, Headquarters (States, Country)
Table 17. United States Gastrointestinal Stromal Tumors Therapeutics Revenue by Domestic Player, (2017-2022) & (USD Million)
Table 18. United States Gastrointestinal Stromal Tumors Therapeutics Revenue Market Share by Domestic Player, (2017-2022)
Table 19. Major Player of Gastrointestinal Stromal Tumors Therapeutics in China, Company Headquarters (Province, Country)
Table 20. China Gastrointestinal Stromal Tumors Therapeutics Revenue by Domestic Player, (2017-2022) & (USD Million)
Table 21. China Gastrointestinal Stromal Tumors Therapeutics Revenue Market Share by Domestic Player, (2017-2022)
Table 22. Major Player of Gastrointestinal Stromal Tumors Therapeutics in Rest of World, Company Headquarters (State, Country)
Table 23. Rest of World Gastrointestinal Stromal Tumors Therapeutics Revenue by Domestic Player, (2017-2022) & (USD Million)
Table 24. Rest of World Gastrointestinal Stromal Tumors Therapeutics Revenue Market Share by Domestic Player, (2017-2022)
Table 25. World Gastrointestinal Stromal Tumors Therapeutics Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 26. World Gastrointestinal Stromal Tumors Therapeutics Revenue by Type (2017-2022) & (USD Million)
Table 27. World Gastrointestinal Stromal Tumors Therapeutics Revenue by Type (2023-2028) & (USD Million)
Table 28. World Gastrointestinal Stromal Tumors Therapeutics Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 29. World Gastrointestinal Stromal Tumors Therapeutics Revenue by Application (2017-2022) & (USD Million)
Table 30. World Gastrointestinal Stromal Tumors Therapeutics Revenue by Application (2023-2028) & (USD Million)
Table 31. Ascentage Pharma Group International Basic Information, Area Served and Competitors
Table 32. Ascentage Pharma Group International Major Business
Table 33. Ascentage Pharma Group International Gastrointestinal Stromal Tumors Therapeutics Product and Services
Table 34. Ascentage Pharma Group International Gastrointestinal Stromal Tumors Therapeutics Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 35. Ascentage Pharma Group International Recent Developments/Updates
Table 36. Ascentage Pharma Group International Competitive Strengths & Weaknesses
Table 37. Bayer AG Basic Information, Area Served and Competitors
Table 38. Bayer AG Major Business
Table 39. Bayer AG Gastrointestinal Stromal Tumors Therapeutics Product and Services
Table 40. Bayer AG Gastrointestinal Stromal Tumors Therapeutics Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 41. Bayer AG Recent Developments/Updates
Table 42. Bayer AG Competitive Strengths & Weaknesses
Table 43. Blueprint Medicines Corp Basic Information, Area Served and Competitors
Table 44. Blueprint Medicines Corp Major Business
Table 45. Blueprint Medicines Corp Gastrointestinal Stromal Tumors Therapeutics Product and Services
Table 46. Blueprint Medicines Corp Gastrointestinal Stromal Tumors Therapeutics Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 47. Blueprint Medicines Corp Recent Developments/Updates
Table 48. Blueprint Medicines Corp Competitive Strengths & Weaknesses
Table 49. Bristol Myers Squibb Co. Basic Information, Area Served and Competitors
Table 50. Bristol Myers Squibb Co. Major Business
Table 51. Bristol Myers Squibb Co. Gastrointestinal Stromal Tumors Therapeutics Product and Services
Table 52. Bristol Myers Squibb Co. Gastrointestinal Stromal Tumors Therapeutics Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 53. Bristol Myers Squibb Co. Recent Developments/Updates
Table 54. Bristol Myers Squibb Co. Competitive Strengths & Weaknesses
Table 55. Deciphera Pharmaceuticals Inc Basic Information, Area Served and Competitors
Table 56. Deciphera Pharmaceuticals Inc Major Business
Table 57. Deciphera Pharmaceuticals Inc Gastrointestinal Stromal Tumors Therapeutics Product and Services
Table 58. Deciphera Pharmaceuticals Inc Gastrointestinal Stromal Tumors Therapeutics Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 59. Deciphera Pharmaceuticals Inc Recent Developments/Updates
Table 60. Deciphera Pharmaceuticals Inc Competitive Strengths & Weaknesses
Table 61. Immunicum AB Basic Information, Area Served and Competitors
Table 62. Immunicum AB Major Business
Table 63. Immunicum AB Gastrointestinal Stromal Tumors Therapeutics Product and Services
Table 64. Immunicum AB Gastrointestinal Stromal Tumors Therapeutics Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 65. Immunicum AB Recent Developments/Updates
Table 66. Immunicum AB Competitive Strengths & Weaknesses
Table 67. Novartis AG Basic Information, Area Served and Competitors
Table 68. Novartis AG Major Business
Table 69. Novartis AG Gastrointestinal Stromal Tumors Therapeutics Product and Services
Table 70. Novartis AG Gastrointestinal Stromal Tumors Therapeutics Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 71. Novartis AG Recent Developments/Updates
Table 72. Novartis AG Competitive Strengths & Weaknesses
Table 73. Pfizer Inc. Basic Information, Area Served and Competitors
Table 74. Pfizer Inc. Major Business
Table 75. Pfizer Inc. Gastrointestinal Stromal Tumors Therapeutics Product and Services
Table 76. Pfizer Inc. Gastrointestinal Stromal Tumors Therapeutics Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 77. Pfizer Inc. Recent Developments/Updates
Table 78. Pfizer Inc. Competitive Strengths & Weaknesses
Table 79. Sun Pharmaceutical Industries Ltd Basic Information, Area Served and Competitors
Table 80. Sun Pharmaceutical Industries Ltd Major Business
Table 81. Sun Pharmaceutical Industries Ltd Gastrointestinal Stromal Tumors Therapeutics Product and Services
Table 82. Sun Pharmaceutical Industries Ltd Gastrointestinal Stromal Tumors Therapeutics Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 83. Sun Pharmaceutical Industries Ltd Recent Developments/Updates
Table 84. Xencor Inc. Basic Information, Area Served and Competitors
Table 85. Xencor Inc. Major Business
Table 86. Xencor Inc. Gastrointestinal Stromal Tumors Therapeutics Product and Services
Table 87. Xencor Inc. Gastrointestinal Stromal Tumors Therapeutics Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 88. Gastrointestinal Stromal Tumors Therapeutics Raw Material
Table 89. Key Manufacturers of Gastrointestinal Stromal Tumors Therapeutics Raw Materials
Table 90. Gastrointestinal Stromal Tumors Therapeutics Typical Distributors
Table 91. Gastrointestinal Stromal Tumors Therapeutics Typical Customers
LIST OF FIGURES
Figure 1. Gastrointestinal Stromal Tumors Therapeutics Picture
Figure 2. World Gastrointestinal Stromal Tumors Therapeutics Total Market Size: 2017 & 2021 & 2028, (USD Million)
Figure 3. World Gastrointestinal Stromal Tumors Therapeutics Total Market Size (2017-2028) & (USD Million)
Figure 4. World Gastrointestinal Stromal Tumors Therapeutics Market Size Market Share by Region (2017-2028)
Figure 5. United States Gastrointestinal Stromal Tumors Therapeutics Market Size (2017-2028) & (USD Million)
Figure 6. China Gastrointestinal Stromal Tumors Therapeutics Market Size (2017-2028) & (USD Million)
Figure 7. Europe Gastrointestinal Stromal Tumors Therapeutics Market Size (2017-2028) & (USD Million)
Figure 8. Japan Gastrointestinal Stromal Tumors Therapeutics Market Size (2017-2028) & (USD Million)
Figure 9. South Korea Gastrointestinal Stromal Tumors Therapeutics Market Size (2017-2028) & (USD Million)
Figure 10. ASEAN Gastrointestinal Stromal Tumors Therapeutics Market Size (2017-2028) & (USD Million)
Figure 11. India Gastrointestinal Stromal Tumors Therapeutics Market Size (2017-2028) & (USD Million)
Figure 12. Gastrointestinal Stromal Tumors Therapeutics Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. Producer Shipments of Gastrointestinal Stromal Tumors Therapeutics by Player Revenue ($MM) and Market Share (%): 2021
Figure 15. Global Four-firm Concentration Ratios (CR4) for Gastrointestinal Stromal Tumors Therapeutics Markets in 2021
Figure 16. Global Four-firm Concentration Ratios (CR8) for Gastrointestinal Stromal Tumors Therapeutics Markets in 2021
Figure 17. United States VS China: Gastrointestinal Stromal Tumors Therapeutics Market Size Market Share Comparison (2017 & 2021 & 2028)
Figure 18. World Gastrointestinal Stromal Tumors Therapeutics Market Size by Type, (USD Million), 2017 & 2021 & 2028
Figure 19. World Gastrointestinal Stromal Tumors Therapeutics Market Size Market Share by Type in 2021
Figure 20. Oral
Figure 21. Non-oral
Figure 22. World Gastrointestinal Stromal Tumors Therapeutics Market Size Market Share by Type (2017-2028)
Figure 23. World Gastrointestinal Stromal Tumors Therapeutics Market Size by Application, (USD Million), 2017 & 2021 & 2028
Figure 24. World Gastrointestinal Stromal Tumors Therapeutics Market Size Market Share by Application in 2021
Figure 25. Hospital
Figure 26. Clinic
Figure 27. Others
Figure 28. World Gastrointestinal Stromal Tumors Therapeutics Market Size Market Share by Application (2017-2028)
Figure 29. Manufacturing Cost Structure Analysis of Gastrointestinal Stromal Tumors Therapeutics in 2021
Figure 30. Manufacturing Process Analysis of Gastrointestinal Stromal Tumors Therapeutics
Figure 31. Gastrointestinal Stromal Tumors Therapeutics Industrial Chain
Figure 32. Distribution Channel Breakdown for Gastrointestinal Stromal Tumors Therapeutics Shipments (%): 2017-2028
Figure 33. Direct Channel Pros & Cons
Figure 34. Indirect Channel Pros & Cons
Figure 35. Methodology
Figure 36. Research Process and Data Source
Figure 1. Gastrointestinal Stromal Tumors Therapeutics Picture
Figure 2. World Gastrointestinal Stromal Tumors Therapeutics Total Market Size: 2017 & 2021 & 2028, (USD Million)
Figure 3. World Gastrointestinal Stromal Tumors Therapeutics Total Market Size (2017-2028) & (USD Million)
Figure 4. World Gastrointestinal Stromal Tumors Therapeutics Market Size Market Share by Region (2017-2028)
Figure 5. United States Gastrointestinal Stromal Tumors Therapeutics Market Size (2017-2028) & (USD Million)
Figure 6. China Gastrointestinal Stromal Tumors Therapeutics Market Size (2017-2028) & (USD Million)
Figure 7. Europe Gastrointestinal Stromal Tumors Therapeutics Market Size (2017-2028) & (USD Million)
Figure 8. Japan Gastrointestinal Stromal Tumors Therapeutics Market Size (2017-2028) & (USD Million)
Figure 9. South Korea Gastrointestinal Stromal Tumors Therapeutics Market Size (2017-2028) & (USD Million)
Figure 10. ASEAN Gastrointestinal Stromal Tumors Therapeutics Market Size (2017-2028) & (USD Million)
Figure 11. India Gastrointestinal Stromal Tumors Therapeutics Market Size (2017-2028) & (USD Million)
Figure 12. Gastrointestinal Stromal Tumors Therapeutics Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. Producer Shipments of Gastrointestinal Stromal Tumors Therapeutics by Player Revenue ($MM) and Market Share (%): 2021
Figure 15. Global Four-firm Concentration Ratios (CR4) for Gastrointestinal Stromal Tumors Therapeutics Markets in 2021
Figure 16. Global Four-firm Concentration Ratios (CR8) for Gastrointestinal Stromal Tumors Therapeutics Markets in 2021
Figure 17. United States VS China: Gastrointestinal Stromal Tumors Therapeutics Market Size Market Share Comparison (2017 & 2021 & 2028)
Figure 18. World Gastrointestinal Stromal Tumors Therapeutics Market Size by Type, (USD Million), 2017 & 2021 & 2028
Figure 19. World Gastrointestinal Stromal Tumors Therapeutics Market Size Market Share by Type in 2021
Figure 20. Oral
Figure 21. Non-oral
Figure 22. World Gastrointestinal Stromal Tumors Therapeutics Market Size Market Share by Type (2017-2028)
Figure 23. World Gastrointestinal Stromal Tumors Therapeutics Market Size by Application, (USD Million), 2017 & 2021 & 2028
Figure 24. World Gastrointestinal Stromal Tumors Therapeutics Market Size Market Share by Application in 2021
Figure 25. Hospital
Figure 26. Clinic
Figure 27. Others
Figure 28. World Gastrointestinal Stromal Tumors Therapeutics Market Size Market Share by Application (2017-2028)
Figure 29. Manufacturing Cost Structure Analysis of Gastrointestinal Stromal Tumors Therapeutics in 2021
Figure 30. Manufacturing Process Analysis of Gastrointestinal Stromal Tumors Therapeutics
Figure 31. Gastrointestinal Stromal Tumors Therapeutics Industrial Chain
Figure 32. Distribution Channel Breakdown for Gastrointestinal Stromal Tumors Therapeutics Shipments (%): 2017-2028
Figure 33. Direct Channel Pros & Cons
Figure 34. Indirect Channel Pros & Cons
Figure 35. Methodology
Figure 36. Research Process and Data Source
